Citigroup Maintains Neutral on BridgeBio Pharma, Raises Price Target to $93

Benzinga · 1d ago
Citigroup analyst Eric Joseph maintains BridgeBio Pharma (NASDAQ:BBIO) with a Neutral and raises the price target from $82 to $93.